A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
2020-07-04
عنوان الدراسة
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
داعم الدراسة
Bayer
دواء الدراسة
Finerenone
رقم بروتوكول الدراسة
BAY 94-8862 16244
حالة الدراسة
Terminated
موقع الدراسة
King Abdulaziz University Hospital (Jeddah)
مرحلة الدراسة
3
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.